Innocan Pharma Corp
F:IP40
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innocan Pharma Corp
F:IP40
|
IL |
|
Telenet Group Holding NV
LSE:0GAF
|
BE |
|
H
|
Hecla Mining Co
LSE:0R0A
|
US |
|
F
|
First Graphene Ltd
OTC:FGPHF
|
AU |
|
Olam Group Ltd
SGX:VC2
|
SG |
|
D
|
Discovery Ltd
JSE:DSBP
|
ZA |
|
Varia US Properties AG
OTC:VARNF
|
CH |
|
C
|
Chocoladefabriken Lindt & Spruengli AG
XBER:LSPP
|
CH |
|
C
|
Credit Agricole SA
SWB:XCA
|
FR |
|
Barry Callebaut AG
F:BCLN
|
CH |
|
Aegon NV
OTC:AEGOF
|
NL |
|
J
|
JOYY Inc
XHAM:0YYA
|
SG |
|
S
|
Shimano Inc
XBER:SHM
|
JP |
|
Apollo Micro Systems Ltd
NSE:APOLLO
|
IN |
|
NCC Ltd
BSE:500294
|
IN |
|
Telefonaktiebolaget LM Ericsson
STO:ERIC B
|
SE |
Innocan Pharma Corp
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items. Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines. What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items.
Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines.
What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
